For anyone in Ogawa trying to locate CJC-1295, the foundational reality is that this compound moves through online research channels. The core insight for Ogawa researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. What consistently distinguishes top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety documentation. The sections below cover what Ogawa researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Ogawa studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade CJC-1295
Evaluating CJC-1295 vendors starts with the COA: request the batch-specific certificate prior to buying, not after. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that lack endotoxin data. Bacteriostatic water is the standard reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that prevents microbial contamination and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order CJC-1295 — ships to Ogawa
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the safety data available for CJC-1295 is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Bacterial endotoxin contamination is the primary safety concern associated with research-grade peptides — verify endotoxin testing is documented in your batch COA before any injectable research application. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
